Trasylol: Patients Shocked At Bayers Failure to Warn
What is Trasylol?
According to Bayer Pharmaceuticals website, www.trasylol.com:
Trasylol is indicated for prophylactic use to reduce perioperative blood loss and the need for blood transfusion in patients undergoing cardiopulmonary [associated with the heart and lungs] bypass in the course of coronary artery bypass graft surgery who are at an increased risk for blood loss and blood transfusion.
Bayers website now contains the following warning about Trasylol:
Trasylol administration may cause fatal anaphylactic or anaphylactoid reactions [a type of allergic reaction]. Fatal reactions have occurred with an initial (test) dose as well as with any of the components of the dose regimen. Fatal reactions have also occurred in situations where the initial (test) does was tolerated. The risk for anaphylactic or anaphylactoid reactions is increased among patients with prior aprotinin [which is Trasylol itself] exposure and a history of any prior aprotinin exposure must be sought prior to Trasylol administration.
However, this warning wasnt made public until 2007 when it was pulled from the market leaving patients to ask
Why did Bayer fail to warn?
Industry experts say that, although Bayer knew about the injuries and deaths associated with Trasylol, it failed to warn the public because of increasing profits from the drugs sale. Trasylol was used on over 4.5 million people one third of those in the United States in the 14 years it was on the market from 1993 to 2007.
If you or a loved one may have been injured or died due to the use of Trasylol, contact an attorney whose practice focuses in this area of law to discuss your situation. The consultation is free and without obligation. To contact a qualified attorney, please click here.